Legend Biotech (LEGN) has released an update.
Legend Biotech Corporation is set to present new data on its CARVYKTI® treatment for multiple myeloma at the upcoming ASCO and EHA meetings, showcasing the therapy’s potential benefits for patients with suboptimal responses to initial treatments and those with high-risk multiple myeloma. These presentations will include findings from the Phase 2 and Phase 3 CARTITUDE clinical trials, offering insights on CARVYKTI®’s efficacy and safety, which may provide hope for developing a cure for this challenging condition.
For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.
